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Abstract
Background: Current techniques used to obtain lung samples have significant limitations and do not provide
reproducible biomarkers of inflammation. We have developed a novel technique that allows multiple sampling
methods from the same area (or multiple areas) of the lung under direct bronchoscopic vision. It allows collection
of mucosal lining fluid and bronchial brushing from the same site; biopsy samples may also be taken. The novel
technique takes the same time as standard procedures and can be conducted safely.
Methods: Eight healthy smokers aged 40–65 years were included in this study. An absorptive filter paper was
applied to the bronchial mucosa under direct vision using standard bronchoscopic techniques. Further samples
were obtained from the same site using bronchial brushings. Bronchoalveolar lavage (BAL) was obtained using
standard techniques. Chemokine (C-C Motif) Ligand 20 (CCL20), CCL4, CCL5, Chemokine (C-X-C Motif) Ligand 1
(CXCL1), CXCL8, CXCL9, CXCL10, CXCL11, Interleukin 1 beta (IL-1β), IL-6, Vascular endothelial growth factor (VEGF),
Matrix metalloproteinase 8 (MMP-8) and MMP-9 were measured in exudate and BAL. mRNA was collected from the
bronchial brushings for gene expression analysis.
Results: A greater than 10 fold concentration of all the biomarkers was detected in lung exudate in comparison to
BAL. High yield of good quality RNA with RNA integrity numbers (RIN) between 7.6 and 9.3 were extracted from
the bronchial brushings. The subset of genes measured were reproducible across the samples and corresponded to
the inflammatory markers measured in exudate and BAL.
Conclusions: The bronchoabsorption technique as described offers the ability to sample lung fluid direct from the
site of interest without the dilution effects caused by BAL. Using this method we were able to successfully measure
the concentrations of biomarkers present in the lungs as well as collect high yield mRNA samples for gene
expression analysis from the same site. This technique demonstrates superior sensitivity to standard BAL for the
measurement of biomarkers of inflammation. It could replace BAL as the method of choice for these
measurements. This method provides a systems biology approach to studying the inflammatory markers of
respiratory disease progression.
Trial registration: NHS Health Research Authority (13/LO/0256).
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Background
Robust and reproducible biomarkers may help further
the understanding of complex heterogeneous respiratory
diseases [1]. Invasive techniques that allow samples to
be obtained direct from the airway may have advantages
over indirect techniques such as sputum. Current sam-
pling techniques such as bronchoalveolar lavage (BAL)
have documented limitations including a lack of sensitiv-
ity and specificity [2]. Furthermore, sampling methods
should allow comparison of proteomic, transcriptomic
and histology data from the same site in the airway.
Such data would allow a correlation that would help
understand disease severity, different phenotypes and re-
sponse to drug therapy [3].
Existing techniques for studying respiratory diseases
include the analysis of BAL and lung biopsies and non-
invasive sample types such as induced sputum and periph-
eral blood. However even though samples can be collected
with relative ease, there are several associated problems [4].
Lack of reproducibility and the effect of dilution on samples
collected reduce considerably the accuracy of the inflam-
matory markers measured. Studies comparing pulmonary
biomarkers from different sample types such as sputum,
BAL and biopsies from the same individual have shown
that there is a large variation in the relative proportion of
inflammatory cells in their profiles and a lack of regularity
is observed between the different sample groups [5].
There is a lack of direct sampling methods that allow
the measurement of markers of disease from specified
areas in the airways. In this pilot study we describe a
novel sampling technique using absorption of lung lining
fluid directly from the site of potential inflammation and
compare it with existing BAL techniques in order to
compare differences in sensitivity and ease of sampling.
Methods
The study was approved by the National Research Ethics
Service Committee South East Coast (13/LO/0256), and all
subjects provided written informed consent. 8 current
smokers, aged 40–65 years of age with a ≥ 10 pack year
smoking history and a positive smokerlyser test were in-
cluded in the study.
Bronchoscopy technique
The bronchoscopy technique was used to collect 3 samples
types; bronchoabsorption membrane (synthetic absorptive
matrix), BAL and bronchial cytology brushings. Bronchial
samples were collected using an Olympus BF-1T20D dir-
ect vision scope bronchoscope (Olympus, UK) with an
Olympus K-203 guide sheath kit (SG-201C, working length
1050 mm and diameter 2.6 mm, with stopper). Subjects
were monitored (vital signs and 3-lead cardiac monitoring)
throughout the bronchoscopy procedure and for at least
2 h thereafter. Topical anaesthesia was achieved with the
application of lidocaine 2, 4 or 10 % to the nasal passages,
(if the nasal route was preferred), pharynx, vocal cords, tra-
chea, the carina, right main bronchus and right middle
lobe. The bronchoscope was passed through the nose or
mouth with the subject’s head tilted at a 45° angle. The
bronchoscope was wedged into a sub segmental bronchus
of the right middle lobe. The following order was adhered
to throughout the bronchoscopy procedure: bronchoab-
sorptive matrix, lavage and bronchial brushings.
Sample collection
Bronchoabsorption exudate - Lung lining fluid was col-
lected using Accuwick Ultra membrane (Pall, USA) which
is a specialised fibrous hydroxylated polyester absorptive
matrix paper. A pre-cut Accuwick strip was guided
through the K-203 guide sheath within the bronchoscope
using Olympus forceps (FB-231D, oval, fenestrated swing
jaw biopsy forceps, working length 1150 mm, and an outer
diameter of 2.0 mm). Strips were left to absorb bronchial
secretions for up to 2 min before they were withdrawn
back through the bronchoscope.
Bronchial lavage - BAL collection was performed
using 4 x 60 mL aliquots (240mL in total) of 0.9 %
saline (Nebusal 7 %) pre-warmed. Each aliquot was
immediately recovered by gentle negative pressure
using a suction pump or directly into a syringe and
collected into a container cooled in ice.
Bronchial brushing - Utilizing an endobronchial dispos-
able Olympus cytology brush (BC-202D-2010, 2 mm brush
diameter, 10 mm brush length, working length 1150 mm)
bronchial brushings were obtained for microarray analysis.
A bronchial brush was guided through the K-203 guide
sheath within the bronchoscope. Once in position, the
brush was gently rotated to collect mucosal cells. The
brush was then removed through the guide sheath.
Sample processing
Bronchoabsorption exudate - Samples were placed in
Spin X® centrifuge tube (Sigma-Aldrich, USA) immedi-
ately upon receipt and the tube centrifuged at 18620 g at
4 °C for 20 min.
Bronchial lavage - The sample was immediately centri-
fuged at 480 g at 4 °C for 10 min.
Bronchial brush - A 0.5 mL aliquot of QIAzol lysis re-
agent (Qiagen, Netherlands) was transferred to tube
containing the bronchial brush. The sample was vor-
texed for 30 s to disperse and lyse the sample.
Biomarker sample analysis
A total of 13 analytes were measured using Luminex 100
multiplex technology (Luminex Corporation, USA) in
bronchoabsorption exudate and BAL samples. The mea-
sured parameters were chemokine (C-C Motif) ligand 20
(CCL20), CCL4, CCL5, chemokine (C-X-C Motif) ligand
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1 (CXCL1), CXCL8, CXCL9, CXCL10, CXCL11, interleu-
kin 1 beta (IL-1β), IL-6, vascular endothelial growth factor
(VEGF), matrix metalloproteinase 8 (MMP-8) and MMP-
9 (R&D Systems, UK).
Gene expression sample analysis
mRNA and miRNA gene expression analyses on the
bronchial brushes was performed by Aros Applied Bio-
technology (Denmark).
Extracted RNA from the bronchial cytology brushes was
analysed using the Agilent Bioanalyser 2100, eukaryote
total RNA nano series II (Agilent, USA) to verify the RNA
integrity number (RIN). Total RNA was used to synthesise
double stranded cDNA which was transcribed to cRNA
using in vitro transcription and purified, the yield was
determined using a Nanodrop (Nanodrop technologies).
Second cycle cDNA was synthesised and hydrolysis was
carried out using the Ambion®WT expression kit
(Ambion, UK). Second cycle cDNA was fragmented and
the single-stranded cDNA was labelled using the Gene-
Chip® Whole Transcript (WT) Sense Target Labelling
Assay (Affymetrix, USA). The fragmented and labelled
single stranded cDNA was hybridized to Affymetrix
Human Transcriptome 2.0 Array (Affymetrix, USA) and
washed and stained using the GeneChip® Hybridization,
Wash and Stain kit (Affymetrix, USA).
Results
Bronchoscopy procedure
All subjects were determined to be healthy (smokers
with no disease as outlined using GOLD – Global initia-
tive for chronic Obstructive Lung Disease) based on
spirometry (Table 1). The bronchoscopy procedure was
generally well tolerated with 2 of the 8 subjects reporting
minor adverse events post procedure (headaches and
chest pain). Sufficient exudate fluid volume was col-
lected from all subjects using the bronchoabsorptive
matrix as indicated in Table 2 and was used to perform
cytokine analysis. Table 2 also indicates the variability in
bronchial fluid retrieval during the BAL process, the
volume of fluid collected ranged between 2.75 and
118.5 mL. Bronchial brush samples were not collected
from 2 subjects due to early termination of the bron-
choscopy procedure. In one instance this occurred due
to bronchoscope malfunction. In the other instance the
subject presented with anomalous lung anatomy in the
right lower lobe, the procedure was completed using a
different lobe but due to the added time, the subject
experienced coughing and the procedure had to be
curtailed.
Biomarker analysis
All analytes were detectable, most in both BAL and the
bronchoabsorptive exudate samples as shown in Figs 1,
2 and 3. The levels of analytes in BAL measured in this
study are comparable to levels of analytes measured in
BAL from smokers seen in previously published literature
(Table 3). The exudate samples tended to exhibit some-
where in the region of a 10-fold increase in analyte levels
compared with BAL samples. Notable exceptions where
the concentration in exudate displayed a 100-fold increase
compared to BAL were CXCL1 (BAL: 375.96 pg/mL;
exudate: 41826.91 pg/mL), CXCL8 (BAL: 23.70 pg/mL;
exudate 2496.79 pg/mL) and IL-6 (BAL: 2.89 pg/mL; ex-
udate: 272.74 pg/mL).
Table 1 Demographic characteristics









Mean (SD) 82.9 (21.0)
Range 67.5–97.5
Body Mass Index (kg/m2)
Mean (SD) 28.2 (2.7)
Range 21.8–31.1
FEV1(L)
Mean (SD) 3.2 (0.6)
Median (range) 3.3 (2.3–4.0)
FEV1 (% predicted)
Mean (SD) 100.1 (10.2)
Median (range) 100.5 (76.0–112.0)
Table 2 Volumes of bronchoalveolar lavage (BAL) and lung
lining fluid (exudate) collected by the bronchoscopy procedure




Subject 1 117.5 42
Subject 2 85 94
Subject 3 105 49
Subject 4 118.5 19
Subject 5 62 75
Subject 6 82 34
Subject 7a,b 29 37
Subject 8a 2.75 66
aBronchial brush not collected due to excessive coughing, resulting in early
termination of bronchoscopy procedure. bAnomalous endobronchial anatomy
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Bronchial brush gene expression
Figure 4 shows the RIN for each of the samples analysed.
RIN values range from 1 (totally degraded) to 10 (intact).
In order to obtain a viable sample with data that can be
analysed using cDNA microarrays, the RIN number
must be as minimally degraded as possible [6]. The sam-
ples analysed following bronchial brush had RIN num-
bers of 7.6–9.3, indicating that the RNA extracted was
of exceptionally high quality.
The gene expression values of the genes CCL2, CCL4,
CCL5, CXCL1, CXCL8, CXCL9, CXCL10, IL-1β, IL-6,
MMP-8, MMP-9 and VEGF are shown in Table 4, for each
of the 6 subjects that bronchial cytology brush scrapes
were collected from. The data shows the expression values
of a limited number of selected genes. Normally micro-
array analysis is dependent on the subtraction technique
but in this pilot study there was no control group
with which to compare the disease state. Nevertheless
the data is able to show high yield of good quality
mRNA that is reproducible in all the samples. The
expression levels for each analyte shown in Table 4
are reproducible across the subjects, with a strong
signal that corresponds to the concentration values
observed in biomarker data obtained.
Discussion
Chronic obstructive pulmonary disease (COPD) is a
common inflammatory disease of the airway and is in-
creasing in incidence throughout the world. The global
prevalence of COPD is approximately 10 % among indi-
viduals over the age of 40 years. The predominant symp-
tom of COPD is shortness of breath which is persistent
and slowly progressive. The clinical symptoms are
caused by inflammation in the airways [1, 7, 8].
Tissue obtained from bronchial biopsies or lung biop-
sies in smokers and patients with COPD has identified
key pathological stages in COPD. The inflammatory
response is characterized by mucous hyperplasia, infil-
tration of T cells (Th1 predominant) and increased num-
bers of neutrophils and macrophages. The progressive
fibrosis seen in the small airways is thought to be re-
sponsible for the irreversible airway narrowing in pa-
tients with COPD [9].
Recent reviews [1, 8] have documented existing bio-
markers in COPD patients but criticized the lack of
information regarding the variability of measurements
and lack of correlation with clinical stage or other
physiological measurements. For example in a recent
meta-analysis (150,000 patients) only sputum neutro-
phils, IL-8, serum TNFα, and C-reactive protein were
correlated (trends only) with COPD stages [10].
Biomarkers should be easily measurable, reproducible
and preferably be straightforward to sample. Recent ad-
vances in transcriptomic and proteomic analyses have
added to the spectrum of biomarkers available but
further studies are needed with repeat measurements in
patients and controls where the phenotype has been
carefully defined.
Fig. 1 Levels of pro-inflammatory cytokines CXCL1 (a), CXCL8 (b), IL-1β (c) and IL-6 (d) measured in bronchoalveolar lavage (BAL) and
bronchoabsorptive matrix exudate
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The respiratory epithelium is thought to be identical
throughout the respiratory tract and similar responses to
inflammation have been reported in the upper and lower
airways [11]. There are several anatomic similarities be-
tween the upper and lower respiratory tracts such as the
columnar epithelial cell lining, the mucosal glands and
vascularity and innervation as well as the early allergic re-
sponse seen during asthma and allergic rhinitis suggesting
a bidirectional link between the two airways [12, 13].
However it remains the case that bronchial samples ob-
tained directly from the lung are thought to be most rep-
resentative of inflammation in the lung and biomarkers
obtained from nasal samples often thought of as surrogate
markers at best [14]. The differences between the nose
and lower airways may influence inflammatory responses;
for example there is a different vasculature in the nose
and in the lower airway. The nose has an extensive system
of capillaries, arteries and venous sinuses, an important
characteristic of nasal mucosa as changes in vascularisa-
tion can cause nasal blockage. However in the bronchi
there is a smooth muscle barrier between the lower airway
mucosa and vascular supply which does not exist in the
nose and is responsible for bronchoconstriction in asthma
[15]. Data shows that there are significant differences in
gene expression between the upper and lower airways in
healthy individuals and that these differences are reduced
during allergic inflammation suggesting the inflammation
of upper airways also effects the lower airway [16].
Two of the most common techniques used gather sam-
ples from the lung are BAL and mucosal bronchial biopsy,
and studies using these techniques provide important
mechanistic data for the evaluation of anti-inflammatory
therapies for asthma and COPD. A European Society Task
Force has issued guidelines for measurements of acellular
components and standardization of BAL [17, 18] and a
similar ATS guideline has also been published to
Fig. 2 Levels of chemokines CCL2 (a), CCL4 (b), CCL5 (c), CXCL9 (d) and CXCL10 (e) measured in bronchoalveolar lavage (BAL) and
bronchoabsorptive matrix exudate
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standardise the measurement of cellular components of
BAL in interstitial lung disease. The reproducibility of
endobronchial biopsy has also been established [19].
There are however inherent problems in the interpret-
ation of samples derived from BAL. By nature BAL fluid
collection is variable as several different factors can im-
pact the quantity and quality of the BAL fluid retrieved.
Studies have shown that the composition of the BAL
fluid collected varies depending on the area the fluid is
collected from and this can affect the proteomic profile
of the supernatant retrieved [20, 21]. Interpreting BAL
findings can be difficult as the procedure cannot be stan-
dardised and accurate quantification of the cellular and
acellular components in BAL fluid cannot be determined
[17, 22]. The causes of variability can be the underlying
disease itself, the suction pressure used during aspiration,
Fig. 3 Levels of structural cytokines MMP-8 (a), MMP-9 (b) and VEGF (c) measured in bronchoalveolar lavage (BAL) and bronchoabsorptive
matrix exudate
Table 3 The range of each analyte measured in bronchoalveolar lavage (BAL) and bronchoabsorptive matrix exudate in this
study compared to the data range of the analytes found in BAL samples from smokers [35–45], BAL samples from COPD
subjects [35, 39, 40, 42, 46–51] and serum samples from smokers [39, 52–56] and serum samples from COPD subjects
[39, 48, 57–60] found in literature. All data are pg/mL
Range in current study Range in literature
Analyte BAL Exudate BAL (smokers) BAL (COPD) Serum (smokers) Serum (COPD)
CCL2 11.7–1168.7 170.0–1131.2 4–200 0–150 0–500 0–600
CCL4 40.7–69.1 171.7–406.7 2–23 No data No data No data
CCL5 3.1–32.3 25.1–60.3 1–120 1–100 0–15 0–40
CXCL1 103–742.7 11741.4–128091.4 0–10000 0–20 No data 0–50
CXCL8 8.3–56.5 460.4–5395.7 2–141.3 121–2500 0–300 1–1780
CXCL9 96.3–117.5 1018.3–3082 0–800 0–1000 0–1000 0–1500
CXCL10 3.5–26.9 151.3–2393.4 0–175 0–180 147–2541 147–2541
IL-1β 2.2–9.6 16.2–523.7 1–20 0–210 9–15 2.1–28.2
IL-6 1.9–5.3 25–943 1–10 0–40 5–11 1.2–33.8
VEGF 7.2–30.6 317.3–1199.7 0–300 0–130 0–76 151–310
MMP-8 163.3–1344.3 7799–101084.7 16–2330 No data 7000–19000 No data
MMP-9 1128.9–6571.2 3500.9–119543.9 0–5000 17.7–8820 0–6500 0–19000
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recovery of lavage fluid, contamination of airways and the
area of lung being lavaged [23]. The retrieval volume of
the samples is highly variable and can be affected by the
age, gender, smoking status and method of retrieval used.
The dilution effect on individual biomarkers and unpre-
dictable absorption of BAL fluid from the lung after instal-
lation is most pronounced in COPD patients and makes
comparison between subject groups and even within pa-
tient comparisons difficult [24].
Alternative techniques exist to avoid the problems asso-
ciated with BAL. Soluble mediators from nasal secretions
can be analysed using a filter paper method [25–27].
Strips of filter paper are placed, one on the nasal septum
and one on the inferior turbinate so as to allow for ab-
sorption of nasal secretions into the matrix of the paper.
After removal, the strips are placed into a buffer and sol-
uble mediators are eluted for later analysis. We have
determined that nasal samples obtained from the filter
paper technique are more sensitive and accurate than
those obtained from nasal lavage [28]. Nasal sampling
techniques can also be used to gather transcriptomic data
directly from the respiratory epithelia. Nasal scrapes and
nasal brushings are an ideal tool for collecting genetic ma-
terial, including mRNA and miRNA, directly from the site
of inflammation.
In this study we have adapted the above nasal tech-
niques to obtain relevant samples from the lower airway;
bronchial mucosal lining fluid for protein analysis and
bronchial brushings for transcriptomic analysis from the
same site. Although not performed in this study it would
be possible to also collect a bronchial biopsy sample
from the same site. The novel bronchoabsorption tech-
nique established in this study has addressed many of
the issues that arise with BAL by directly sampling the
Fig. 4 The electropherogram for each of the 6 samples (subject 1- subject 6) analysed using the 2100 Agilent Bioanalyser shows the RNA
Integrity Number (RIN) obtained before microarray analysis was performed
Table 4 Gene expression values from bronchial brushes. Data are log transformed of fluorescent intensity
Gene Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6
CCL2 8.96 6.84 7.27 6.83 9.14 7.11
CCL4 6.30 6.82 6.32 6.39 6.41 6.48
CCL5 7.43 7.27 8.16 7.60 8.35 7.65
CXCL1 7.84 8.45 8.52 8.62 8.75 8.64
CXCL8 8.47 8.58 8.95 8.89 8.83 8.24
CXCL9 6.17 6.04 6.94 6.91 6.49 6.47
CXCL10 6.91 5.44 7.57 7.74 7.37 8.06
IL-1β 6.74 6.25 6.10 6.22 7.10 6.43
IL-6 5.36 6.03 5.44 5.42 5.35 5.48
MMP-8 3.58 4.76 3.63 3.76 3.47 3.56
MMP-9 6.49 6.98 6.75 6.53 6.59 6.59
VEGF 7.64 7.73 7.10 8.01 7.67 7.98
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bronchial mucosal lining fluid and avoiding any compli-
cations of contamination and dilution.
This pilot study demonstrates the utility of the tech-
niques to harvest lower airway samples. The study also
allows comparison of the existing standard technique
(BAL) with the novel bronchoabsorption method. Table 2
illustrates the variability of the volume of fluid retrieved
after BAL, which becomes even more variable in COPD
patients. In contrast exudate levels not only demonstrate
less variability in retrieval volume but more importantly
the exudate fluid is undiluted. The analysis of each ana-
lyte shows at least 10 fold higher concentration in exud-
ate than BAL. This increase in measurable levels
increases the sensitivity of the assay markedly and for
analytes present at low levels may be the difference in
being able to detect the biomarker of interest.
The BAL technique is thought to sample mainly from
the distal airway in comparison to the precise anatomical
location of the sample obtained using the filter paper
technique. It is certainly possible that differences seen in
the concentrations of inflammatory markers may be re-
lated to where the sample was taken from. However, the
respiratory epithelium is uniform throughout the re-
spiratory tract (unified hypothesis [11]) and therefore a
similar pattern of inflammatory response should be seen
in proximal and distal airways.
The levels of inflammatory mediators are partially gen-
etically determined and information obtained from the
genome scale can give information on respiratory disease
pathogenesis. GWAS of biomarkers help locate novel
genetic determinants and pathways of complex airway
diseases and determine the extent of the genetic role on
systemic inflammation [29].
In order to perform GWAS, blood samples are collected
from COPD subjects and mRNA is extracted to perform
gene expression analysis [30, 31]. However systemic
markers for inflammation found in blood samples from
COPD patients have not been determined as accurate in-
dicators of inflammation in the lungs. Systemic inflamma-
tion could be an effect of the inflammation COPD
mediators cause in the airways or a separate component
of the disease which is independent of the processes oc-
curring in the lungs [32, 33]. Therefore gene analysis of
samples representative of the processes occurring in the
lungs is required.
This technique allows the collection of direct mucosal
samples from the same site as the lung exudate samples
which enables gene expression analysis to be performed
using the mRNA extracted from bronchial mucosal cells.
This systems biology approach of sample collection gives
a complete picture of molecular and transcriptomic
markers of inflammation that allows for the subtyping of
airway diseases. The results reflect the ability of the
method used to be able to collect samples of high yield
and quality as seen in Fig. 4. RNA integrity numbers of
greater than 7 are indicative of good quality genomic
samples which would allow the comparison of the tran-
scriptional profiles obtained. Samples obtained using our
novel technique ranged from 7.6 up to 9.3. While most
microarray data analysis is performed via a comparison
with control groups or baseline levels, our study did not
include a control group. The data from this study serves
to illustrate the viability of the samples collected using
this technique and the reproducibility of the expression
levels observed of the subset of genes of interest across
the patient samples.
Biomarker profiling improves the ability to screen for
novel markers of disease to aid with drug development.
Treatments focusing on anti-inflammatory agents that
target epithelial lung injury and subsequent inflamma-
tion are gaining importance and momentum. The ap-
proach to future developments of novel drug targets are
to stop disease progression and prevent further decline
in lung function by blocking inflammatory processes and
structural remodelling events taking place in the airways
[34]. Therefore targeting the blocking of specific cyto-
kines and chemokines implicated in the inflammatory
process may be important in this process.
Conclusions
The current study has validated a novel direct bronchial
sampling technique allowing for the measurement of bio-
markers direct from the site of pulmonary inflammation.
Using direct vision bronchoscopes the novel method uses
a combined approach to collect multiple samples such as
biopsies, lung exudates and BAL from the same site to
help shed light on a less superficial understanding of dif-
ferent disease mechanisms and builds towards a systems
biology approach to understanding the disease. At the
same time this technique enables the collection of samples
from multiple sites in the same individual using a vali-
dated bronchoscopy method without increasing the time
or the risk to the patients involved. This procedure can be
utilised to compare the responses between varying disease
and non-disease states to help understand the pathogen-
esis of obstructive airway diseases.
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